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Abstract Coronary heart disease (CHD) remains the
leading cause of death in Germany despite statin use to
reduce low-density lipoprotein cholesterol (LDL-C) levels;
improving lipids beyond LDL-C may further reduce
cardiovascular risk. A ﬁxed-dose combination of extended-
release niacin (ERN) with laropiprant (LRPT) provides
comprehensive lipid management. We adapted a decision-
analytic model to evaluate the economic value (incre-
mental cost-effectiveness ratio [ICER] in terms of costs per
life-years gained [LYG]) of ERN/LRPT 2 g over a lifetime
in secondary prevention patients in a German setting. Two
scenarios were modelled: (1) ERN/LRPT 2 g added to
simvastatin 40 mg in patients not at LDL-C goal with
simvastatin 40 mg; (2) adding ERN/LRPT 2 g compared
with titration to simvastatin 40 mg in patients not at LDL-C
goal with simvastatin 20 mg. In both scenarios, adding
ERN/LRPT was cost-effective relative to simvastatin
monotherapy at a commonly accepted threshold of €30,000
per LYG; ICERs for ERN/LRPT were €13,331 per LYG in
scenario 1 and €17,684 per LYG in scenario 2. Subgroup
analyses showed that ERN/LRPT was cost-effective in
patients with or without diabetes, patients aged B65 or
[65 years and patients with low baseline high-density
lipoprotein cholesterol levels; ICERs ranged from €10,342
to €15,579 in scenario 1, and from €14,081 to €20,462 in
scenario 2. In conclusion, comprehensive lipid manage-
ment with ERN/LRPT 2 g is cost-effective in secondary
prevention patients in Germany who have not achieved
LDL-C goal with simvastatin monotherapy.
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Introduction
Statin therapy to reduce low-density lipoprotein cholesterol
(LDL-C) is the recommended ﬁrst-line treatment option for
German patients with elevated LDL-C [1] and at high risk
for cardiovascular events. Despite the use of statins, how-
ever, coronary heart disease (CHD) remains the leading
cause of death in Germany [2], and the healthcare costs of
CHD in Germany in 2006 were the highest in Europe, at
€7.9 billion [3]. Improving lipid parameters beyond the
reduction in LDL-C achieved with statins may further
reduce the risk of cardiovascular events in patients with
dyslipidaemia, because low levels of high-density lipo-
protein cholesterol (HDL-C) and elevated triglyceride
levels are associated with increased cardiovascular risk
[4–7]. In particular, statin therapy does not reduce the
increased cardiovascular risk associated with low HDL-C
levels [8]. The Dyslipidemia International Study (DYSIS)
found that low levels of HDL-C and high triglyceride
levels are highly prevalent in Europe [9, 10].
Niacin reduces levels of LDL-C and triglycerides and is
the most effective agent for increasing HDL-C levels [11].
Niacin at doses C2 g, alone or in combination with statins,
reduces atherosclerotic CHD and may reduce coronary
events in patients with cardiovascular disease [12–16].
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DOI 10.1007/s10198-011-0309-zHowever, immediate-release niacin is associated with
ﬂushing in more than 90% of patients who take the drug
[17–20] and frequently leads to complete discontinuation
of treatment. Extended-release niacin (ERN) is associated
with less ﬂushing than the immediate-release niacin for-
mulations [21]. Nonetheless, ﬂushing remains a problem
with ERN; treatment must be initiated at a low dose
(375 mg in Germany; 500 mg in the USA) and complete
discontinuation remains common. A retrospective cohort
study of primary care patients in Germany found that 50%
of patients treated with ERN alone discontinued therapy
after the ﬁrst prescription, and only 22% of patients con-
tinued treatment for a full year [22]. Moreover, the average
maintenance dose was just 840 mg, which is below the
recommended therapeutic dose range of 1,000–2,000 mg/
day.
Acetylsalicylic acid (aspirin) at doses of at least 325 mg
is modestly effective in the mitigation of ﬂushing severity
[23, 24]. However, it is infrequently used, must be taken
30 min before the niacin dose and is not effective as a
rescue medication [25, 26]. Niacin-induced ﬂushing is
primarily mediated by prostaglandin D2 (PGD2), which
stimulates the PGD2 receptor-1 (DP1) in the skin [27].
Laropiprant (LRPT) is a potent, once-daily, highly selec-
tive DP1 antagonist [28]. Combining LRPT with ERN
could therefore inhibit much of the PGD2-mediated ﬂush-
ing, allowing more patients to achieve and maintain clini-
cally effective doses of niacin. In clinical trials in patients
with primary hypercholesterolaemia or mixed dyslipid-
aemia, the ERN/LRPT 2 g combination provided compre-
hensive lipid management similar to ERN 2 g alone, but
with improved tolerability [29, 30]. ERN/LRPT is contra-
indicated in patients with signiﬁcant or unexplained hepatic
dysfunction, or with active peptic ulcer disease.
Most patients with dyslipidaemia will receive ﬁrst-line
treatment with a statin; simvastatin is the most commonly
prescribed statin in Germany. To illustrate the economic
value of add-on ERN/LRPT 2 g in a German setting, we
conducted a cost-effectiveness analysis of ERN/LRPT
added to simvastatin monotherapy for the prevention of
CHD death, non-fatal myocardial infarction (MI) or
non-fatal angina in patients with established CHD not at
goal LDL-C (i.e. secondary prevention patients). Patients
with established CHD were chosen for the analysis as this
group is at a greater risk of cardiovascular events compared
with primary prevention patients and is therefore more
likely to require treatments in addition to statins to improve
lipid parameters such as HDL-C and triglycerides. Three
treatments were considered: (1) simvastatin 40 mg mono-
therapy; (2) addition of ERN/LRPT to simvastatin 40 mg
in patients not at LDL-C goal with simvastatin 40 mg alone
and (3) addition of ERN/LRPT compared with titration to
simvastatin 40 mg in patients not at LDL-C goal with
simvastatin 20 mg alone.
Materials and methods
Model design
A lifetime decision-analytic model was developed to
explore the costs and health outcomes associated with the
use of ERN/LRPT in combination with simvastatin
compared with simvastatin monotherapy. This was based
on a previously published model developed to project the
long-term beneﬁts and cost of alternative lipid-lowering
strategies in patients with hypercholesterolaemia, which
has been described in detail elsewhere [31, 32]. Brieﬂy,
progression of CHD in secondary prevention patients was
modelled with Microsoft Excel and Visual Basic software
using a Markov process with an annual cycle between
discrete health states (Fig. 1). The individual patient proﬁle
data for patients who met the inclusion criteria from the
IMS database form the basis for the cohort in the economic
analysis. Unlike standard cohort analyses where risk
proﬁles are generated from population averages, these
analyses are conducted with the actual patient data. This
method allows the transition probabilities to vary from one
proﬁle to the next. Patients can either experience a recur-
rent CHD event (fatal CHD, non-fatal MI or non-fatal
angina) or die from non-CHD causes.
The probability of recurrent CHD in patients with
established CHD was estimated for each year modelled
using published Framingham risk equations from
D’Agostino et al. [33]. The impact of treatment was
modelled by a mean change in the patient’s lipid level
(total cholesterol [TC] and HDL-C), which in turn alters
the patient’s risk of CHD. Because LDL-C is generally
calculated from measuring TC and HDL-C, modelling
changes in TC and HDL-C alone is sufﬁcient to capture
changes in LDL-C. The Framingham risk equations from
Anderson and colleagues were used to estimate the prob-
ability of fatal CHD, non-fatal MI or non-fatal angina [34].
Because of potential differences in the likelihood of fatal
CHD, non-fatal MI or non-fatal angina in primary and
secondary prevention patients, the relative rates of these
events observed in primary and secondary prevention
patients in the Framingham study [33] were used to adjust
the allocation of secondary events. Age- and sex-speciﬁc
non-CHD mortality was calculated by subtracting age- and
sex-speciﬁc CHD mortality from the all-cause mortality
(Table 1). Data for all-cause mortality were obtained from
the Federal Health System Information Monitoring website
[35] and the Federal Statistics Ofﬁce [36].
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patients reached an age of 100 years. For each patient
proﬁle, lifetime costs and life-years are accumulated over
the speciﬁed time horizon. The incremental cost-effec-
tiveness ratio is calculated by:
 CE    CS
 QE    QS
ð1Þ
where:  CE is the average lifetime cost across all patients
receiving ERN/LRTP,  CS is the average lifetime cost
across all patients receiving simvastatin 40 mg,  QE is the
average life-years across all patients receiving ERN/LRTP,
and  QS is the average life-years across all patients receiving
simvastatin 40 mg.
Model inputs
Efﬁcacy of ERN/LRPT and comparators
The effects on the lipid proﬁle (TC and HDL-C) of addition
of ERN/LRPT to simvastatin monotherapy were based on
data from a 24-week phase 3 clinical trial in 1,613 patients
with primary hypercholesterolaemia or mixed dyslipid-
aemia, 67% of whom were receiving a statin at baseline; in
this study, total cholesterol decreased by 8.5% and HDL-C
increased by 20% [30]. The effects of doubling the dose of
simvastatin from 20 to 40 mg were based on ﬁndings from
the Ezetimibe and Simvastatin versus Double Statin Reach
New Lipid Treatment Goals (EASEGO) study in 367
patients with type 2 diabetes and/or CHD, in which total
cholesterol decreased by 6.6% and HDL-C increased by
1% [37]. ERN/LRPT 2 g added to simvastatin 10, 20 or
40 mg also signiﬁcantly improved lipid parameters beyond
the LDL-C reductions observed with simvastatin alone in a
12-week study in 1,398 patients with primary hypercho-
lesterolaemia or mixed hyperlipidaemia [38].
Patient proﬁles
Patients aged 50–80 years with CHD and LDL-C C100 mg/
dL on simvastatin were selected from a population-based
primary care database in Germany (IMS Health) that
contains representative data on prescriptions and lipids for
1% of the German population in 2007 (Table 2). The
appropriate International Classiﬁcation of Disease (ICD)
code was used to determine whether patients had CHD or
diabetes; patients were also assumed to have diabetes if they
had been given a prescription for anti-diabetic medication.
Patient baseline characteristics were determined separately
for each of the scenarios modelled. Only the earliest
recorded TC, LDL-C and HDL-C lipid proﬁle for each
patient (not earlier than January 2007) was included, in
order to reﬂect the ﬁrst possible intervention point for
physicians. Incomplete data were available for systolic
blood pressure (SBP) and smoker status; the mean SBP was
imputed and the proportion of smokers was estimated by
randomly assigning values to patients with missing data,
based on the data observed. Data on left ventricular
hypertrophy were obtained from Cook et al., 2004 [31]. In
No event:
  No event last year
  MI last year
  Angina last year
Fatal event:
 Non-CHD  death
 CHD  death
Cholesterol
intervention program
Enter:
new secondary
prevention 
patients
Age 1 year:
update risk
factors
Calculate risk of
non-CHD death
and CHD
Non-fatal CHD:
 Secondary  MI
 Secondary  angina
Fig. 1 Model ﬂow.
CHD, coronary heart disease;
MI, myocardial infarction
Table 1 Age- and sex-speciﬁc non-CHD mortality
Age, years Non-CHD mortality per 100,000 participants in 2007
Men Women
45–54 367 209
55–64 858 475
65–74 1938 1051
75–84 5081 3561
85–99 12668 12102
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patients receiving simvastatin 40 mg were considered for
evaluation.
Costs and resource use
All costs were determined from a payer perspective in the
German setting (Table 3). Costs of CHD events (fatal
CHD, non-fatal MI or non-fatal angina) were for 2004 and
were based on data used for the original model [31].
The unit costs of simvastatin 20 and 40 mg and ERN/
LRPT 2 g were based on the pharmacy retail prices for the
largest pack size in Germany in October 2009. In a
conservative approach, simvastatin costs were those for the
largest pack size and the cheapest available generic for-
mulation [39].
There were no extra physician visit costs to consider
with regard to the addition of ERN/LRPT, as physicians in
Germany receive a quarterly amount of money per patient
regardless of the number of visits within the quarter.
Aggregated costs for the measurement of lipid parameters
(TC, LDL-C, HDL-C and triglycerides) were €1( €0.25
each). It was assumed that physicians monitored the whole
lipid proﬁles of the patients. Costs associated with adverse
events were excluded (as these were expected to be low),
consistent with the approach adopted in similar, previous
cost-effectiveness analyses [31, 40]. Utilities were not
considered in this analysis, as utilities currently have only a
minor role in the determination of drug cost-effectiveness
in Germany. Costs and health beneﬁts were discounted at a
rate of 3% per annum, in accordance with guidance from
the Institut fu ¨r Qualita ¨t und Wirtschaftlichkeit im
Gesundheitswesen (IQWiG).
Model outputs
Cardiovascular events (fatal and non-fatal MI, angina) and
life expectancy (life-years gained [LYGs]) were projected
over a lifetime (until surviving patients reached an age of
100 years) for all treatments. The accumulated costs were
projected over a lifetime and were determined for all
treatments studied. Incremental cost-effectiveness ratios
(ICERs) were calculated as the incremental cost per LYG
for ERN/LRPT compared with simvastatin monotherapy.
An ICER of €30,000 per LYG was assumed as a generally
accepted willingness to pay threshold in Germany [41].
Table 2 Baseline characteristics for patients included in the model
Parameter Scenario 1 Scenario 2
Simvastatin 40 mg (n = 707) Simvastatin 20 mg (n = 886)
Age, years
a 67.8 ± 0.3 68.8 ± 0.3
TC, mg/dL 207.3 ± 1.0 205.6 ± 1.0
LDL-C, mg/dL 125.5 ± 1.1 124.9 ± 0.8
HDL-C, mg/dL 52.3 ± 0.5 52.7 ± 0.4
Triglycerides, mg/dL 175.7 ± 4.6 164.7 ± 2.9
SBP, mmHg
b 138.1 ± 1.2 135.6 ± 0.8
Diabetes, % 36.4 37.7
Smoker, %
b 24.8 20.7
Menopause Assumed for women aged C50 years Assumed for women aged C50 years
Left ventricular hypertrophy, %
c 35.0 35.0
Data are shown as mean ± SE unless otherwise stated
a Age was restricted to 50–80 years, in accordance with the HPS2-THRIVE outcomes study [48]
b Estimated from a subsample of patients
c Not available in IMS Health database. Published echocardiographic or electrocardiographic prevalence estimates [31]
HDL-C High-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SBP systolic blood pressure
Table 3 Summary of costs used in the model
Parameter Cost in year 1, € Cost in year 2, €
Angina
a 4416.00 662.00
Non-fatal MI (1st year)
a 6971.00 1046.00
CHD death
a 3095.00 NA
ERN/LRPT 2 g
b 1.76 NA
Simvastatin 20 mg
c 0.15 NA
Simvastatin 40 mg
c 0.33 NA
Laboratory and visit costs
d 1.00 NA
CHD Coronary heart disease, ERN extended-release niacin, LRPT
laropiprant, MI myocardial infarction, NA not applicable
a Cost per year; from Cook et al. [31]
b Cost per day; price as of 8 October 2009
c Cost per day; the lowest generic price as of 8 October 2009
d Cost per visit
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Univariate sensitivity analyses
Univariate sensitivity analyses were performed to test the
robustness of the model outputs to changes in discount rates
(from base-case 3% to 0%, 5%, 7% or 10%), event costs
(20% increase or 20% decrease), CHD risk (20% increase
or 20% decrease), cost of ERN/LRPT 2 g (10% increase or
10% decrease), cost of simvastatin (20% decrease), time
until beneﬁt (2 years, rather than 1 year), discontinuation of
ERN/LRPT owing to ﬂushing (7.4% of patients) [42] and
mean maintenance dose (ERN/LRPT 1.5 g/day [50% on 1g/
day and 50% on 2 g/day] rather than 2 g/day).
Subgroup analyses
The long-term projection of cardiovascular events and
mortality, and the cost-effectiveness of ERN/LRPT were
determined as described above for several predeﬁned
population subgroups: patients with or without diabetes;
patients with HDL-C below the norm (\40 mg/dL in men
and \45 mg/dL in women; as deﬁned by the European
Society of Cardiology [43]); patients with a TC/HDL-C
ratio C4.5; and patients aged B65 years or[65 years.
Results
Long-term projection of cardiovascular events
In scenario 1, the addition of ERN/LRPT 2 g to simvastatin
40 mg was associated with an additional undiscounted
0.80 years during the course of a lifetime compared with
simvastatin 40 mg alone (Table 4). In scenario 2, adding
ERN/LRPT 2 g to simvastatin 20 mg was associated with
an additional undiscounted 0.75 life-years compared with
simvastatin 20 mg monotherapy; by contrast, titration of
simvastatin 20 to 40 mg added 0.22 life-years (Table 4).
Cost-effectiveness of adding ERN/LRPT to simvastatin
In the base case for scenario 1 in patients receiving sim-
vastatin 40 mg, the projected ICER for adding ERN/LRPT
was €13,331 per LYG compared with simvastatin 40 mg
alone (Table 5). Adding ERN/LRPT to simvastatin 40 mg
is therefore a cost-effective treatment option relative to the
generally accepted threshold of €30,000 per LYG in
Germany.
In the base case for scenario 2, adding ERN/LRPT 2 g
to simvastatin 20 mg was associated with an ICER of
€17,684 per LYG compared with up-titration of simvasta-
tin from 20 to 40 mg day. Thus, adding ERN/LRPT to
simvastatin 20 mg monotherapy was cost-effective relative
to doubling the dose of simvastatin.
Sensitivity analyses
Univariate sensitivity analysis
UnivariatesensitivityanalysisshowedthatadditionofERN/
LRPT2 gremainedcost-effective(ICERbelow€30,000per
LYG) in both scenarios independent of changes in discount
rate,eventcosts,medicationcosts,thelevelofbaselineCHD
risk and mean maintenance dose of ERN/LRPT (1.5 g/day
Table 4 Projected undiscounted life expectancy and life-years gained with addition of ERN/LRPT 2 g in patients not at LDL-C goal on
simvastatin monotherapy
Scenario 1 (n = 707) Scenario 2 (n = 886)
Simvastatin 40 mg ERN/LRPT 2 g ?
simvastatin
40 mg
Simvastatin 20 mg Simvastatin
20 mg titrated
to 40 mg
ERN/LRPT 2 g ? simvastatin 20 mg
Remaining
life expectancy,
years
LYG Remaining
life expectancy,
years
LYG LYG versus
simvastatin
20 mg alone
LYG versus
simvastatin
up-titration
All patients 13.28 0.80 12.82 0.22 0.75 0.53
CHD without diabetes 14.13 0.73 13.63 0.21 0.70 0.49
CHD with diabetes 11.79 0.93 11.46 0.25 0.85 0.60
Age B65 years 17.62 1.25 17.75 0.37 1.22 0.86
Age[65 years 11.16 0.58 10.88 0.17 0.57 0.40
Low HDL-C
a 12.27 0.93 12.21 0.27 0.90 0.63
TC/HDL-C ratio C4.5 12.75 0.98 12.10 0.26 0.90 0.63
CHD Coronary heart disease, ERN extended-release niacin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cho-
lesterol, LRPT laropiprant, LYG life-years gained, TC total cholesterol
a Low HDL-C: men,\40 mg/dL; women,\45 mg/dL
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and discontinuation rates for ERN/LRPT (Table 5). ICERs
ranged from €11,012–19,707 per LYG for scenario 1 and
€14,603–26,101 per LYG for scenario 2.
Subgroup analyses
Subgroup analyses showed that compared with the overall
patient cohort, the projected LYG associated with addi-
tional ERN/LRPT treatment in both scenarios was greater
in patients aged B65 years, and those with diabetes, low
HDL-C or a TC/HDL-C ratio C4.5 (Table 5). There were
no notable differences between the scenarios.
Adding ERN/LRPT to simvastatin 40 mg in scenario 1
was cost-effective in all of the subgroups analysed (ICER
below €30,000 per LYG). Similarly, adding ERN/LRPT to
simvastatin 20 mg was cost-effective compared with
titration of simvastatin 20 to 40 mg in scenario 2. Across
all subgroups in both scenarios, ICERs remained below
€20,462 per LYG (Table 5). In both scenarios, ICERs
tended to be lower than the overall cohort in the subgroups
of patients with diabetes, patients aged B65 years, patients
Table 5 Univariate sensitivity analysis and patient subgroup analysis
Cost per LYG, €
Scenario 1
ERN/LRPT ? simvastatin 40 mg
vs simvastatin 40 mg alone
Scenario 2
ERN/LRPT ? simvastatin 20 mg
vs simvastatin up-titration
Base case 13,331 17,684
Time until beneﬁt, 2 years 14,862 19,772
Discount rate, %
0 11,012 14,603
5 15,027 19,928
7 16,828 22,307
10 19,707 26,101
Event costs, % change
?20 13,245 17,593
-20 13,418 17,775
ERN/LRPT costs, % change
?10 14,698 19,682
-10 11,964 15,686
CHD risk, % change
?20 11,599 15,326
-20 15,940 21,234
Simvastatin costs, % change
-20 13,308 18,050
ERN/LRPT discontinuation rate owing to ﬂushing
7.4% 13,331 18,167
Mean maintenance dose, 1.5 g/day 11,582 15,981
Subgroup analysis
CHD without diabetes 15,579 20,462
CHD with diabetes 10,342 14,081
Age B65 years 11,783 15,680
Age[65 years 14,704 19,119
Low HDL-C
a 10,749 14,283
TC/HDL-C ratio C4.5 10,696 14,176
Costs and effects discounted at 3% per annum
CHD Coronary heart disease, ERN extended-release niacin, HDL-C high-density lipoprotein cholesterol, LRPT laropiprant, LYG life-year gained
a Low HDL-C: men,\40 mg/dL; women,\45 mg/dL
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C4.5.
Discussion
Although statins are an established and effective ﬁrst-line
treatment option in Germany for patients with elevated
levels of LDL-C [1], treatments to improve other lipid
parameters in addition to LDL-C may be needed to further
reduce the risk of cardiovascular events in patients with
CHD and dyslipidaemia. ERN/LRPT increases HDL-C
levels and also reduces LDL-C and triglyceride levels
[30, 38]. Our adapted decision-analytic model showed that
addition of ERN/LRPT 2 g to statin monotherapy was
projected to be cost-effective (i.e. ICERs within a com-
monly accepted cost-effectiveness threshold of €30,000 per
LYG) in two scenarios reﬂective of clinical practice in
Germany; (1) addition of ERN/LRPT to simvastatin 40 mg
in patients not at LDL-C goal with simvastatin 40 mg
alone; and (2) addition of ERN/LRPT compared with
titration to simvastatin 40 mg in patients not at LDL-C goal
with simvastatin 20 mg alone.
We modelled the use of ERN/LRPT in two different
scenarios using representative patient proﬁles from a
German ofﬁce-based setting. In scenario 1, ERN/LRPT 2 g
was added to high-dose statin monotherapy (simvastatin
40 mg), reﬂecting the aggressive, ‘‘ﬁre-and-forget’’
approach to the treatment of elevated LDL-C that is
recommended for secondary prevention of CHD in, for
example, the UK [44]. However, this approach leaves
considerable scope for further reduction in CHD risk by
treatment to increase HDL-C and lower triglycerides,
because monotherapy with statins such as simvastatin has
limited effects on HDL-C and triglycerides [45]. Our
adapted model showed that the improvements in lipid
parameters associated with adding ERN/LRPT 2 g to
simvastatin 40 mg were associated with a projected
increase in life expectancy of 0.8 years. ERN/LRPT
treatment under this scenario was cost-effective, with an
ICER of €13,331 per LYG.
In scenario 2, ERN/LRPT added to simvastatin 20 mg
was compared with up-titration of simvastatin 20 to 40 mg.
This scenario is relevant to German clinical practice
because simvastatin 20 mg is the most commonly pre-
scribed dose in Germany. Although titration to simvastatin
40 mg would appear a logical option for patients not at
LDL-C goal with simvastatin 20 mg, in fact, doubling the
dose of a statin yields only a modest (3–7%) incremental
reduction in LDL-C and little or no incremental beneﬁt on
HDL-C [46]. Our adapted model showed that comprehen-
sive lipid management with ERN/LRPT added to simva-
statin 20 mg provided a projected 0.75 LYG, compared
with 0.22 LYG with doubling the dose of simvastatin.
Addition of ERN/LRPT 2 g to simvastatin 20 mg was cost-
effective in this scenario, with an ICER of €17,684 per
LYG compared with doubling the simvastatin dose.
Subgroup analyses showed that adding ERN/LRPT to
simvastatin was cost-effective (ICERs below €30,000 per
LYG) in both scenarios for CHD patients with or without
diabetes, patients aged B65 years or [65 years, patients
with low HDL-C (\40 mg/dL in men and \45 mg/dL in
women) as deﬁned by the European Society of Cardiology
[43] and patients with a TC/HDL-C ratio C4.5. ERN/LRPT
thus represents a cost-effective treatment option for the
prevention of cardiovascular events in secondary preven-
tion patients when added to simvastatin monotherapy at
either dose.
The strengths of our analysis include the use of baseline
characteristics from actual patients in Germany, although it
should be noted that these were not necessarily represen-
tative of German patients who received lipid-modifying
treatment in specialty care. We also modelled realistic
treatment scenarios typical of German clinical practice
(initial aggressive LDL-C lowering with simvastatin
40 mg, or treatment-to-target with simvastatin 20 mg as
initial treatment followed by titration to simvastatin 40 mg
for patients not at LDL-C goal). Furthermore, our model
was not limited to a ﬁxed time span, but projected
cardiovascular morbidity and mortality (and hence cost-
effectiveness) over a lifetime (up to an age of 100 years).
Sensitivity analyses showed that our model was robust to
reasonable changes in patient characteristics, and cost and
efﬁcacy inputs. In particular, the model was not sensitive to
changes in the costs of events; this is important because it
indicates that there is no limitation associated with the use
in our model of event costs that were not inﬂated from
2004 values (under the assumption that while some event
costs will have increased, others will have decreased).
It is reasonable to consider the cost-effectiveness of
ERN/LRPT in the context of other niacin-based treatment
options. Our ﬁndings are broadly consistent with a cost-
effectiveness analysis by Roze and colleagues based on the
Arterial Biology for the Investigation of the Treatment
Effects of Reducing Cholesterol (ARBITER) 2 study and
conducted from a French payer perspective; this study
concluded that increasing HDL-C levels with ERN 1 g/day
in patients with low HDL-C on statin monotherapy was
cost-effective for the prevention of CHD events, with an
ICER for ERN 1 g/day added to statin monotherapy of
€20,645 per LYG [40]. It is worth noting that the Roze
et al. study included a simple sensitivity analysis to
investigate the effects of different levels of compliance
(expressed as the proportion of drop-outs) on the cost-
effectiveness of ERN 1 g/day. The projected cost-effec-
tiveness of ERN was not markedly altered by drop-out
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compared with €20,454, €20,225 and €19,938 per LYG for
drop-out rates of 10%, 20% and 40%, respectively. While
drop-outs were associated with a reduction in LYG, this is
offset by the reduction in drug acquisition costs. These
results suggest that the assumption in our model that
patients were fully adherent to the treatment regimen is
unlikely to have any notable impact on the projected cost-
effectiveness of ERN/LRPT. The real-life clinical effec-
tiveness of ERN/LRPT is likely to be greater than that of
ERN because of the reduced incidence of ﬂushing and
consequent lower rates of medication discontinuation [30].
The main limitation of our model is the use of risk
equations [33, 34] to predict CHD events based on treat-
ment-induced changes in lipid parameters (in particular,
increases in HDL-C); this was necessary because clinical
trials evaluating the effects on cardiovascular outcomes of
adding ERN/LRPT to statin treatment remain to be com-
pleted. We feel that this is a reasonable approach given that
clinical trials have demonstrated beneﬁcial effects of niacin
on cardiovascular outcomes [12–16] and that ERN/LRPT
improves lipid parameters as effectively as other niacin-
based treatments such as ERN monotherapy [29, 30].
Furthermore, in a lipid goal attainment study in German
patients with CHD, the addition of ERN/LRPT to statin
compared with continuation of statin therapy increased the
proportion of patients achieving LDL-C goal by 32.7% in
men and 42.8% in women. Signiﬁcantly more patients
(absolute difference 29.3% in men and 38.2% in women)
on ERN/LRPT added to statin attained their goal/normal
levels for LDL-C, HDL-C and triglycerides [47]. The
ongoing HPS2-THRIVE (Treatment of High density lipo-
protein to Reduce the Incidence of Vascular Events) study
will determine whether ERN/LRPT added to simvastatin
with or without ezetimibe improves cardiovascular out-
comes in patients with established cardiovascular disease
compared with add-on placebo [48]. The use of Framing-
ham risk equations in our model is consistent with treat-
ment guidelines such as those from the US National
Cholesterol Education Program Adult Treatment Panel
[11] and the Second Joint Task Force of European and
other Societies on coronary prevention [49], and with
previous cost-effectiveness studies of lipid-modifying
treatments [31, 40]. It must be accepted, however, that the
Framingham risk equations are based on US population
data and may therefore not precisely reﬂect risk in a
German population.
Some additional limitations of our model should also be
noted. Patient characteristics such as SBP were assumed to
be constant with increasing age; this is a common
assumption in studies of this type and inevitably results in
an underestimate of CHD risk in the elderly and hence a
conservative estimate of the cost-effectiveness of ERN/
LRPT in these patients. Nevertheless, the increase in risk
associated with age itself was taken into account in the
model, and so, some of the effects of increasing age, as
well as changes in other risk factors, would be accounted
for indirectly. Incidence of left ventricular hypertrophy was
estimated; however, these estimates were based on data
from secondary prevention patients with CHD in Germany.
Our model also excluded indirect costs and costs of adverse
events and assumed perfect adherence to medication; all of
these approaches are consistent with previous cost-effec-
tiveness analyses of lipid-modifying treatments [31, 40].
Sensitivity analyses showed that the cost-effectiveness of
ERN/LRPT 2 g was not affected when a discontinuation
rate of 7.4% for ERN/LRPT (the discontinuation rate
owing to ﬂushing observed in clinical trials [42]) was
included in the model. Finally, the aim of this analysis was
to evaluate the cost-effectiveness of ERN/LRPT in
Germany, and so, these results cannot necessarily be
extrapolated to other countries and settings.
Conclusion
The results of this analysis indicate that comprehensive
lipid management with ERN/LRPT 2 g is cost-effective in
secondary prevention patients in Germany who have not
achieved LDL-C goal with simvastatin monotherapy.
ICERs for additional treatment with ERN/LRPT were
below the commonly accepted cost-effectiveness threshold
of €30,000 per LYG in two scenarios reﬂective of German
clinical practice: (1) addition of ERN/LRPT compared with
simvastatin 40 mg alone in patients not at LDL-C goal
despite aggressive treatment with simvastatin 40 mg and
(2) addition of ERN/LRPT compared with doubling the
dose of simvastatin to 40 mg in patients not at LDL-C goal
on simvastatin 20 mg. Model robustness was conﬁrmed in
several univariate sensitivity analyses, for which the ICERs
remained considerably below the €30,000 per LYG
threshold. The ongoing HPS2-THRIVE study will assess
the potential role of comprehensive lipid management with
ERN/LRPT in reducing cardiovascular morbidity and
mortality beyond statins.
Acknowledgments All authors participated in the development and
writing of the paper and approved the ﬁnal manuscript for publication.
The authors take full responsibility for the content of the paper and
thank Dr Richard White and Dr Jenny Handford (Oxford Pharma-
Genesis
TM Ltd) for medical writing support, editorial assistance, and
collation and incorporation of comments from all authors. This work
was funded by MSD Sharp & Dohme GmbH, Haar, Germany. GVM
and KJK are employees of MSD Sharp & Dohme, and GMD is an
employee of Merck & Co., Inc., and all are therefore eligible for
stock/stock options in the company.
372 G. V. Michailov et al.
123Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Hockley, T., Gemmill, M.: European Cholesterol Guidelines
Report. www.policy-centre.com/downloads/European-Cholesterol-
Guidelines07.pdf (2007). Accessed 20 November 2009
2. World Health Organization. Mortality country fact sheet 2006
(Germany). http://www.who.int/whosis/mort/proﬁles/mort_euro_
deu_germany.pdf (2006). Accessed 18 November 2009
3. British Heart Foundation Statistics Website. Health care costs of
CHD by country, 2006, EU. http://www.heartstats.org/temp/
ESspTabsp12.2spweb08.xls (2006). Accessed 20 November 2009
4. Austin, M.A., Hokanson, J.E., Edwards, K.L.: Hypertriglyceri-
demia as a cardiovascular risk factor. Am. J. Cardiol. 81, 7B–12B
(1998)
5. McBride, P.: Triglycerides and risk for coronary artery disease.
Curr. Atheroscler. Rep. 10, 386–390 (2008)
6. Assmann, G., Schulte, H., von Eckardstein, A., Huang, Y.: High-
density lipoprotein cholesterol as a predictor of coronary heart
disease risk. The PROCAM experience and pathophysiological
implications for reverse cholesterol transport. Atherosclerosis
124(Suppl), S11–S20 (1996)
7. Drexel, H., Aczel, S., Marte, T., Benzer, W., Langer, P., Moll,
W., Saely, C.H.: Is atherosclerosis in diabetes and impaired
fasting glucose driven by elevated LDL cholesterol or by
decreased HDL cholesterol? Diabetes Care 28, 101–107 (2005)
8. Jafri, H., Alsheikh-Ali, A.A., Karas, R.H.: Statin therapy does not
reduce the increased cardiovascular risk associated with low
levels of high-density lipoprotein cholesterol: evidence from
randomized controlled trials. Circulation 120, S500 (2009).
(Abstract 1423)
9. Gitt, A.K., Kastelein, J.P.P.: Predominant types of dyslipidemia
in patients with coronary heart disease treated with statins in
Europe and Canada: data from the dyslipidemia international
study. Eur. Heart. J. 30(Suppl 1), 591 (2009). (Abstract 3543)
10. Gitt, A.K., Kastelein, J.P.P.: High prevalence of dyslipidemia in
18, 574 patients treated with statins in Europe and Canada:
Results of the dyslipidemia international study. Eur. Heart. J.
30(Suppl 1), 303 (2009). (Abstract 1796)
11. NCEP. Third Report of the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III) ﬁnal report. Circulation 106, 3143–3421 (2002)
12. The coronary drug project. JAMA 221, 918 (1972)
13. Cloﬁbrate and niacin in coronary heart disease. JAMA 231,
360–381 (1975)
14. Brown, B.G., Hillger, L., Zhao, X.Q., Poulin, D., Albers, J.J.:
Types of change in coronary stenosis severity and their relative
importance in overall progression and regression of coronary
disease. Observations from the FATS Trial. Familial Athero-
sclerosis Treatment Study. Ann. N. Y. Acad. Sci.748, 407–417
(1995). (discussion 417–418)
15. Brown, B.G., Zhao, X.Q., Chait, A., Fisher, L.D., Cheung, M.C.,
Morse, J.S., Dowdy, A.A., Marino, E.K., Bolson, E.L., Alaupo-
vic, P., Frohlich, J., Albers, J.J.: Simvastatin and niacin, antiox-
idant vitamins, or the combination for the prevention of coronary
disease. N. Engl. J. Med. 345, 1583–1592 (2001)
16. Canner, P.L., Berge, K.G., Wenger, N.K., Stamler, J., Friedman,
L., Prineas, R.J., Friedewald, W.: Fifteen year mortality in
Coronary Drug Project patients: long-term beneﬁt with niacin.
J. Am. Coll. Cardiol. 8, 1245–1255 (1986)
17. Knopp, R.H., Ginsberg, J., Albers, J.J., Hoff, C., Ogilvie, J.T.,
Warnick, G.R., Burrows, E., Retzlaff, B., Poole, M.: Contrasting
effects of unmodiﬁed and time-release forms of niacin on lipo-
proteins in hyperlipidemic subjects: clues to mechanism of action
of niacin. Metabolism 34, 642–650 (1985)
18. Illingworth, D.R., Stein, E.A., Mitchel, Y.B., Dujovne, C.A.,
Frost, P.H., Knopp, R.H., Tun, P., Zupkis, R.V., Greguski, R.A.:
Comparative effects of lovastatin and niacin in primary hyper-
cholesterolemia. A prospective trial. Arch. Intern. Med. 154,
1586–1595 (1994)
19. Mills, E., Prousky, J., Raskin, G., Gagnier, J., Rachlis, B.,
Montori, V.M., Juurlink, D.: The safety of over-the-counter nia-
cin. A randomized placebo-controlled trial [ISRCTN18054903].
BMC. Clin. Pharmacol. 3, 4 (2003)
20. Birjmohun, R.S., Hutten, B.A., Kastelein, J.J., Stroes, E.S.:
Increasing HDL cholesterol with extended-release nicotinic acid:
from promise to practice. Neth. J. Med. 62, 229–234 (2004)
21. Abbott Pharmaceuticals. Niaspan (Niacin extended-release tab-
lets) US prescribing information. http://www.rxabbott.com/pdf/
niaspan.pdf (2005). Accessed 9 November 2009
22. Krobot, K.J., Michailov, G.V., Wagner, A.: Four-year treatment
practice with extended-release niacin in Germany: adherence,
treatment gaps and daily maintenance dose. Eur. Heart. J.
30(Suppl 1), 590 (2009). (Abstract 3541)
23. Dunn, R.T., Ford, M.A., Rindone, J.P., Kwiecinski, F.A.: Low-
dose aspirin and ibuprofen reduce the cutaneous reactions fol-
lowing niacin administration. Am. J. Ther. 2, 478–480 (1995)
24. Whelan, A.M., Price, S.O., Fowler, S.F., Hainer, B.L.: The effect
of aspirin on niacin-induced cutaneous reactions. J. Fam. Pract.
34, 165–168 (1992)
25. Trovato, A.T., Norquist, J.M., Rhodes, T., McQuarrie, K., Miller,
T.B., Paolini, J.F., Watson, D.J.: The impact of niacin-induced
ﬂushing during the ﬁrst week of therapy in a real world setting.
J. Am. Coll. Cardiol. 51, A255 (2008). (Abstract 1019–1150)
26. Kamal-Bahl, S., Watson, D.J., Ambegaonkar, B.M.: Patients’
experiences of niacin-induced ﬂushing in clinical practice: a
structured telephone interview. Clin. Ther. 31, 130–140 (2009)
27. Cheng, K., Wu, T.J., Wu, K.K., Sturino, C., Metters, K., Got-
tesdiener, K., Wright, S.D., Wang, Z., O’Neill, G., Lai, E.,
Waters, M.G.: Antagonism of the prostaglandin D2 receptor 1
suppresses nicotinic acid-induced vasodilation in mice and
humans. Proc. Natl. Acad. Sci. U S A 103, 6682–6687 (2006)
28. Sturino, C.F., O’Neill, G., Lachance, N., Boyd, M., Berthelette,
C., Labelle, M., Li, L., Roy, B., Scheigetz, J., Tsou, N., Aubin,
Y., Bateman, K.P., Chauret, N., Day, S.H., Levesque, J.F., Seto,
C., Silva, J.H., Trimble, L.A., Carriere, M.C., Denis, D., Greig,
G., Kargman, S., Lamontagne, S., Mathieu, M.C., Sawyer, N.,
Slipetz, D., Abraham, W.M., Jones, T., McAuliffe, M., Piechuta,
H., Nicoll-Grifﬁth, D.A., Wang, Z., Zamboni, R., Young, R.N.,
Metters, K.M.: Discovery of a potent and selective prostaglandin
D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-ﬂuoro-5-
(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic
acid (MK-0524). J. Med. Chem. 50, 794–806 (2007)
29. Paolini, J.F., Mitchel, Y.B., Reyes, R., Kher, U., Lai, E., Watson,
D.J., Norquist, J.M., Meehan, A.G., Bays, H.E., Davidson, M.,
Ballantyne, C.M.: Effects of laropiprant on nicotinic acid-induced
ﬂushing in patients with dyslipidemia. Am. J. Cardiol. 101,
625–630 (2008)
30. Maccubbin, D., Bays, H.E., Olsson, A.G., Elinoff, V., Elis, A.,
Mitchel, Y., Sirah, W., Betteridge, A., Reyes, R., Yu, Q., Kuz-
netsova, O., Sisk, C.M., Pasternak, R.C., Paolini, J.F.: Lipid-
modifying efﬁcacy and tolerability of extended-release niacin/
laropiprant in patients with primary hypercholesterolaemia or
mixed dyslipidaemia. Int. J. Clin. Pract. 62, 1959–1970 (2008)
Cost-effectiveness of extended-release niacin/laropiprant 373
12331. Cook, J.R., Yin, D., Alemao, E., Davies, G., Krobot, K.J., Veltri,
E., Lipka, L., Badia, X.: Cost-effectiveness of ezetimibe coad-
ministration in statin-treated patients not at cholesterol goal:
application to Germany, Spain and Norway. Pharmacoeconomics
22(Suppl 3), 49–61 (2004)
32. Cook, J.R., Yin, D., Alemao, E., Drummond, M.: Development
and validation of a model to project the long-term beneﬁt and cost
of alternative lipid-lowering strategies in patients with hyper-
cholesterolaemia. Pharmacoeconomics 22(Suppl 3), 37–48
(2004)
33. D’Agostino, R.B., Russell, M.W., Huse, D.M., Ellison, R.C.,
Silbershatz, H., Wilson, P.W., Hartz, S.C.: Primary and sub-
sequent coronary risk appraisal: new results from the Framing-
ham study. Am. Heart J. 139, 272–281 (2000)
34. Anderson, K.M., Odell, P.M., Wilson, P.W., Kannel, W.B.:
Cardiovascular disease risk proﬁles. Am. Heart J. 121, 293–298
(1991)
35. Das Informationssystem der Gesundheitsberichterstattung des
Bundes. http://www.gbe-bund.de/ (2007). Accessed 12 March
2009
36. Statistisches Bundesamt Deutschland. http://www.destatis.de/
jetspeed/portal/cms/ (2007). Accessed 12 March 2009
37. Roeters van Lennep, H.W., Liem, A.H., Dunselman, P.H., Dal-
linga-Thie, G.M., Zwinderman, A.H., Jukema, J.W.: The efﬁcacy
of statin monotherapy uptitration versus switching to ezetimibe/
simvastatin: results of the EASEGO study. Curr. Med. Res. Opin.
24, 685–694 (2008)
38. Gleim, G., Ballantyne, C.M., Liu, N., Thompson-Bell, S., McC-
rary Sisk, C., Pasternak, R.C., Mitchel, Y., Paolini, J.F.: Efﬁcacy
and safety proﬁle of co-administered ER niacin/laropiprant and
simvastatin in dyslipidaemia. Br. J. Cardiol. 16, 90–97 (2009)
39. Lauer-Fischer. Lauer-Taxe Online. http://www.lauer-ﬁscher.
de/LF/Seiten/Produkte/Lauer-Taxe?online/Lauer-Taxe?online.
aspx (2009). Accessed October 2009
40. Roze, S., Ferrieres, J., Bruckert, E., Van Ganse, E., Chapman,
M.J., Liens, D., Renaudin, C.: Cost-effectiveness of raising HDL
cholesterol by adding prolonged-release nicotinic acid to statin
therapy in the secondary prevention setting: a French perspective.
Int. J. Clin. Pract. 61, 1805–1811 (2007)
41. Botteman, M.F., Meijboom, M., Foley, I., Stephens, J.M., Chen,
Y.M., Kaura, S.: Cost-effectiveness of zoledronic acid in the
prevention of skeletal-related events in patients with bone
metastases secondary to advanced renal cell carcinoma: appli-
cation to France, Germany, and the United Kingdom. Eur.
J. Health. Econ. (2010). doi:10.1007/s10198-010-0272-0
42. Maccubbin, D., Koren, M.J., Davidson, M., Gavish, D., Paster-
nak, R.C., Macdonell, G., Mallick, M., Sisk, C.M., Paolini, J.F.,
Mitchel, Y.: Flushing proﬁle of extended-release niacin/laropip-
rant versus gradually titrated niacin extended-release in patients
with dyslipidemia with and without ischemic cardiovascular
disease. Am. J. Cardiol. 104, 74–81 (2009)
43. Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G.,
Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S.,
Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S.,
Knapton, M., Perk, J., Priori, S.G., Pyorala, K., Reiner, Z., Rui-
lope, L., Sans-Menendez, S., Scholte op Reimer, W., Weissberg,
P., Wood, D., Yarnell, J., Zamorano, J.L., Walma, E., Fitzgerald,
T., Cooney, M.T., Dudina, A., Vahanian, A., Camm, J., De
Caterina, R., Dean, V., Dickstein, K., Funck-Brentano, C., Fi-
lippatos, G., Hellemans, I., Kristensen, S.D., McGregor, K.,
Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Altiner, A.,
Bonora, E., Durrington, P.N., Fagard, R., Giampaoli, S., Hem-
ingway, H., Hakansson, J., Kjeldsen, S.E., Larsen, M.L., Mancia,
G., Manolis, A.J., Orth-Gomer, K., Pedersen, T., Rayner, M.,
Ryden, L., Sammut, M., Schneiderman, N., Stalenhoef, A.F.,
Tokgozoglu, L., Wiklund, O., Zampelas, A.: European guidelines
on cardiovascular disease prevention in clinical practice: execu-
tive summary. Eur. Heart J. 28, 2375–2414 (2007)
44. Cooper, A., Nherera, L., Calvert, N., O’Flynn, N., Turnbull, N.,
Robson, J., Camosso-Steﬁnovic, J., Rule, C., Browne, N., Ritchie,
G., Stokes, T., Mannan, R., Bath, P., Brindle, P., Gill, P., Gujral,
R., Hogg, M., Marshall, T., Minhas, R., Pavitt, L., Reckless, J.,
Rutherford, A., Thorogood, M., Wood, D.: Clinical guidelines
and evidence review for lipid modiﬁcation: cardiovascular risk
assessment and the primary and secondary prevention of car-
diovascular disease. http://www.guidance.nice.org.uk/CG67/
Guidance/pdf/English (2008). Accessed 22 November 2009
45. Todd, P.A., Goa, K.L.: Simvastatin. A review of its pharmaco-
logical properties and therapeutic potential in hypercholestero-
laemia. Drugs 40, 583–607 (1990)
46. Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney,
J.M., Miller, E., Cain, V.A., Blasetto, J.W.: Comparison of the
efﬁcacy and safety of rosuvastatin versus atorvastatin, simvasta-
tin, and pravastatin across doses (STELLAR* Trial). Am.
J. Cardiol. 92, 152–160 (2003)
47. Michailov, G.V., Davies, G.M., Buono, J., Sazonov, V., Krobot,
K.J.: Lipid goal attainment in German CHD patients receiving
ER-Niacin/Laropiprant added to statin therapy. Clin. Res. Car-
diol. 99(Suppl 2), P159 (2010). doi:10.1007/s00392-010-1200-0
48. Clinicaltrials.gov. NCT00461630: Treatment of HDL to reduce
the incidence of vascular events HPS2-THRIVE. http://www.
clinicaltrials.gov/ct2/show/NCT00461630 Accessed 22 Novem-
ber 2009
49. Prevention of coronary heart disease in clinical practice. Recom-
mendations of the Second Joint Task Force of European and other
Societies on coronary prevention. Eur. Heart. J. 19, 1434–1503
(1998)
374 G. V. Michailov et al.
123